GLP-1 Outcomes at Ivím Health: Peer-Reviewed Results from 2,300+ Patients
Ivím Health is a physician-led virtual obesity medicine practice that has published two peer-reviewed studies documenting GLP-1 outcomes in over 2,300 patients. Across more than 1,100 patients on semaglutide and tirzepatide, Ivím patients achieved average weight loss results that exceeded many published pharmaceutical clinical trial benchmarks — including the SURMOUNT trials for tirzepatide.
The reason, according to the research: the care model.
What Our Research Found
Ivím Health has published two peer-reviewed studies in Obesity Pillars, a leading journal in obesity medicine led by Chief Medical Officer Dr. Jessica Duncan. Both studies evaluated outcomes in patients following the Ivím care protocol — a comprehensive virtual approach to GLP-1 therapy built around individualized dosing, continuous provider access, and structured lifestyle support.
Results: Semaglutide (1,131 Patients)
Average total body weight loss at 52 weeks
Average total body weight loss at 68 weeks
Patients who lost at least 5% of body weight
Patients who lost 10% or more
Patients who lost 15% or more
Patients who lost 20% or more
Results: Tirzepatide (1,166 Patients)
Average total body weight loss at 52 weeks
Average total body weight loss at 68 weeks
Patients who lost at least 5% of body weight
Patients who lost 10% or more
Patients who lost 15% or more
Patients who lost 20% or more
How Do Ivím Health Results Compare to Clinical Trials?
The landmark SURMOUNT-1 trial for tirzepatide reported an average weight loss of approximately 20.9% at 72 weeks at the highest dose (15 mg). In the Ivím tirzepatide study, patients achieved an average of 26.5% weight loss at 72 weeks — and 67% of those patients never exceeded a 10 mg dose.
The SUSTAIN and STEP trials for semaglutide reported average weight loss of approximately 14.9% at 68 weeks. Ivím patients on semaglutide achieved 21.8% at 68 weeks.
These are not head-to-head randomized controlled trials and should not be interpreted as such. But the consistency of results across two large real-world patient cohorts, both published in peer-reviewed literature, points to a meaningful pattern: comprehensive clinical support may significantly enhance what GLP-1 medications can do.
The Ivím Care Model
Ivím Health’s outcomes are built on what the studies call the IVIM protocol — an Individualized Virtual Integrative Medicine approach that wraps clinical, behavioral, and technological support around every patient’s GLP-1 treatment.
Board-certified clinical oversight. Every Ivím patient is treated by a board-certified obesity medicine physician or nurse practitioner. Providers conduct regular consultations throughout the program to monitor progress, adjust dosing, and manage side effects.
Personalized dosing. Medication is titrated based on each patient’s individual response — not a fixed schedule. This approach allows providers to optimize results while minimizing side effects. In the tirzepatide study, the majority of patients achieved significant weight loss without ever reaching the maximum therapeutic dose.
Unlimited provider access. Patients can schedule an unlimited number of 15-minute virtual consultations with their care team. More than one-third of tirzepatide study patients used the virtual waiting room for immediate access to a provider.
Functional health coaching. Ivím’s certified health coaches work with patients on nutrition, physical activity, and behavioral change — focused on root-cause lifestyle modification, not generic advice.
A technology platform built for adherence. All patients have access to Ivím’s mobile app and online dashboard for weight tracking, daily check-ins, care team messaging, and educational resources. In the tirzepatide study, 100% of patients used the online platform and 88% used the mobile app.
Peer community and support. Patients can opt into an Ivím wellness community to connect with others on similar journeys, join weekly live Q&A sessions with health coaches, and access ongoing educational programming.
“The medication is the starting point. What we’ve shown is that the model around it — the access, the individualization, the support — is what drives results patients can sustain.”
— Dr. Jessica Duncan, Chief Medical Officer, Ivím Health
Frequently Asked Questions
Ivím Health has published two peer-reviewed studies in Obesity Pillars documenting average weight loss of 21.8% on semaglutide at 68 weeks and 26.5% on tirzepatide at 72 weeks. These results exceed many published pharmaceutical clinical trial benchmarks. To our knowledge, they represent some of the highest real-world outcomes published in peer-reviewed literature for GLP-1 therapy in a telehealth setting.
The Research, Cited
Gonzalez, J. et al. “Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes.” Obesity Pillars, 2025. https://doi.org/10.1016/j.obpill.2025.100146
Gonzalez, J. et al. “Tirzepatide real-world outcomes and treatment adherence using the individualized virtual integrative (IVIM) protocol.” Obesity Pillars, 2025. https://doi.org/10.1016/j.obpill.2025.100159
See What Comprehensive
GLP-1 Care Can Do
If you’re curious about GLP-1 therapy — or if you’re already on it and not getting the results you expected — Ivím Health was built for patients like you.
